Scienmag

JULY 18, 2025

In a groundbreaking study that promises to redefine how we understand immune-mediated kidney disease, researchers have unveiled PathoPlex, a cutting-edge multiplexing technology that offers unprecedented insight into the cellular and molecular mechanisms driving renal pathology. By harnessing the power of spatially resolved, high-dimensional imaging, this innovative platform allows scientists to map disease processes at a nanometric resolution, illuminating complex interactions that were previou

Antibody 52

Antibody In-Vivo In-Vitro Research 52

Pharma Times

JULY 15, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership MHRA approves first oral treatment for hereditary angioedema attacks by John Pinching | 15th Jul 2025 | News Sebetralstat offers injection-free relief for patients aged 12 and over The MHRA has approved sebetralstat (Ekterly) as the first oral, on-demand treatment for hereditary angioedema (HAE) attacks in pa

DNA 81

DNA Genetics Medicine Trials 81

Scienmag

JULY 15, 2025

In the relentless battle against antibiotic-resistant superbugs, methicillin-resistant Staphylococcus aureus (MRSA) represents one of the most formidable threats to global public health. Its notorious ability to evade conventional antimicrobials has fueled severe infections that are increasingly difficult to treat with existing therapies. However, a pioneering study, recently published in Nature Biotechnology , unveils an innovative approach that could redefine how we address these persistent ba

Antibody 59

Antibody Immune Response Bacteria In-Vivo 59

JAMA Internal Medicine

JULY 13, 2025

This Clinical Insight reviews the lifestyle factors important for patients receiving glucagon-like peptide-1 and dual receptor agonists to manage weight.

110

110

Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group

Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.

Compliance

pharmaphorum

JULY 15, 2025

Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.

Genetics 97

Genetics 97

ACRP blog

JULY 16, 2025

Clinical trials are typically seen as engines of innovation, but for economically disadvantaged individuals, they can also be a gateway to care—particularly for chronic diseases that are expensive to manage. For those living with gastrointestinal (GI) conditions like ulcerative colitis, Crohn’s disease, nonalcoholic fatty liver disease (NAFLD), or NAFLD’s advanced form, nonalcoholic steatohepatitis (NASH), clinical trials may offer access to diagnostics, treatments, and specialists that would ot

Clinical Trials 66

Clinical Trials Clinical Trials Trials Clinical Research 66

STAT News

JULY 11, 2025

The Food and Drug Administration rejected a marketing application from Capricor Therapeutics for a cell therapy to treat Duchenne muscular dystrophy, the company said Friday.  In its letter to Capricor, the FDA said the company’s application “does not meet the statutory requirement for substantial evidence of effectiveness” and requested additional clinical data, the company said.

Gene Therapy 134

Gene Therapy Gene Marketing Drugs 134

Pharma Times

JULY 15, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership NHS England secures access to new cystic fibrosis treatment ALYFTREK by John Pinching | 15th Jul 2025 | News Vertex’s once-daily triple therapy approved for eligible patients aged six and over Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK (deutivacaftor/tez

DNA 129

DNA Medicine Licensing Licensing 129

pharmaphorum

JULY 15, 2025

An obesity therapy developed Hengrui Pharma and Kailera is being prepared for its first regulatory submission, in China

Development 85

Development 85

Drug Discovery World podcast

JULY 17, 2025

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “ Decoding diseases: The AI renaissance in clinical trials ” and “ Advancing antibody discovery with AI ”. In the first article, Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and sta

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

Advertisement

Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness

Trials

Scienmag

JULY 17, 2025

In the evolving landscape of brain-wide association studies, a recent investigation underscores a pivotal strategy that intriguingly challenges conventional wisdom: extending the duration of functional magnetic resonance imaging (fMRI) scans not only sharpens predictive accuracy but also reduces overall research costs. This paradigm shift confronts the traditional notion that shorter scans paired with larger sample sizes always yield the most efficient outcomes, revealing instead a nuanced equil

Research 59

Research Engineer Development Medicine 59

STAT News

JULY 16, 2025

As a medical oncologist, one of the first threats I inform new patients about during the informed consent process for cancer treatment is how vulnerable they now are to infections. Cancer weakens the immune system, and common therapies on which we rely, such as chemotherapy, further diminish the body’s ability to protect itself from infections.

143

143

Bio Pharma Dive

JULY 14, 2025

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

Drugs 187

Drugs Gene Therapy Gene Life Science 187

pharmaphorum

JULY 15, 2025

The UK Biobank has completed the world's largest whole body imaging project, compiling more than a billion scans from 100,000 volunteers.

Biobanking 76

Biobanking 76

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Rethinking Clinical Trials

JULY 14, 2025

Adrian Hernandez and Rebecca Sullenger In this Friday’s Rethinking Clinical Trials Grand Rounds, Adrian Hernandez and Rebecca Sullenger of Duke University will present “State of Clinical Trials: An Analysis of ClinicalTrials.gov.” They will be joined by a discussion panel that will include Sara Bristol Calvert of the Clinical Trials Transformation Initiative (CTTI) and Karen Chiswell and Christopher J.

Clinical Trials 162

Clinical Trials Clinical Trials Trials Medicine 162

Scienmag

JULY 15, 2025

In recent years, the escalating prevalence of obesity has emerged as a critical public health concern worldwide, with profound implications across generations. A groundbreaking systematic review and meta-analysis recently published in the International Journal of Obesity illuminates the intricate associations between maternal body mass index (BMI) measured before or during pregnancy and the metabolic profiles of their offspring throughout the life course.

Insulin 59

Insulin Gene Expression Research DNA 59

Pharma Times

JULY 14, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Pierre Fabre secures China approval for BRAFTOVI combination in colorectal cancer by John Pinching | 14th Jul 2025 | News New treatment targets BRAFV600E-mutant mCRC after prior therapy Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with cetu

DNA 108

DNA Vaccination Vaccine Trials 108

Velocity Clinical Research

JULY 17, 2025

Velocity Clinical Research, the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies to automate and streamline the notoriously complex payments reconciliation process in clinical trials. This collaboration marks a milestone in applying advanced artificial intelligence (AI) to one of the industry’s most persistent administrative challenges.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

PharmTech

JULY 15, 2025

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug reformulation and delivery strategies.

Drugs 45

Drugs 45

pharmaphorum

JULY 15, 2025

The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.

Drugs 94

Drugs 94

Scienmag

JULY 14, 2025

In recent years, the intricate relationship between major depressive disorder (MDD) and the heightened risk of Alzheimer’s disease and related dementias (ADRD) has drawn increasing scientific attention. Despite wide recognition of this connection, the biological underpinnings that link these two prevalent and debilitating conditions remain elusive. A groundbreaking investigation leveraging data from the UK Biobank now sheds critical light on this complex interplay, unveiling proteogenomic signat

Protein 59

Protein Genetics Biobanking Genomics 59

World of DTC Marketing

JULY 16, 2025

Pharma is a complicated business. The walls between departments—Medical Affairs, Marketing, Regulatory, Legal—are supposed to protect scientific integrity and patient safety. But too often, these walls turn into silos. One of the most significant disconnects in the pharmaceutical industry today is between Medical Affairs and the commercial side of the business.

Marketing 244

Marketing Compliance Branding Drugs 244

Advertisement

Clinical Supply

XTalks

JULY 17, 2025

CapsoVision, Inc. completed its initial public offering (IPO), raising $27.5 million before underwriting discounts and commissions. The company sold 5.5 million shares at $5.00 each. Trading under the ticker “CV,” shares began on the Nasdaq Capital Market on July 2, 2025. Current Share Price: What Is Small Bowel Endoscopy? Small bowel endoscopy is a procedure used to examine the small intestine, a long and narrow part of the digestive tract that plays a crucial role in nutrient absorption.

FDA Approval 88

FDA Approval Production Development Marketing 88

Pharma Times

JULY 17, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership One Biosciences raises €15 million to advance single-cell oncology platform by John Pinching | 17th Jul 2025 | News Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic plat

Trials 87

Trials Clinical Trials Clinical Trials Clinical Development 87

pharmaphorum

JULY 15, 2025

LEO Pharma has licensed a medicine for a rare form of psoriasis from Boehringer Ingelheim, plugging a gap in its near-term product portfolio.

Licensing 85

Licensing Licensing Medicine Drugs 85

World of DTC Marketing

JULY 13, 2025

One of the most common questions I hear from prospective clients is: “How would you build a great product website?” It’s a smart question—especially in healthcare, where your product site isn’t just a digital brochure. It’s a potential turning point for someone seeking answers about their health. A well-designed website can spark interest, build trust, and encourage patients to take the next step: asking their doctor about your treatment.

Production 157

Production Branding Marketing Doctor 157

Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk

In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?

Compliance

Medical Xpress

JULY 16, 2025

The UK's pioneering licensed IVF technique to reduce the risk of mitochondrial diseases carried out in Newcastle has seen eight babies born, research shows.

DNA 98

DNA Licensing Licensing Research 98

Bio Pharma Dive

JULY 16, 2025

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government to negotiate pay-for-performance deals with the manufacturers of products like Casgevy and Lyfgenia.

Gene Therapy 170

Gene Therapy Gene Manufacturing Production 170

Pharma Times

JULY 17, 2025

Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression by John Pinching | 17th Jul 2025 | News First patient dosed in BUOY-1 study targeting MDD with or without anxious distress Seaport Therapeutics has dosed the first patient in its phase 2b BUOY-1 trial of GlyphAllo, a novel oral prodr

Trials 87

Trials Clinical Trials Clinical Trials 87

Scienmag

JULY 16, 2025

In the relentless quest to unravel the mysteries of neonatal brain injuries, researchers have taken a significant leap forward in early diagnosis and intervention strategies for hypoxic-ischemic encephalopathy (HIE). This devastating condition, resulting from insufficient oxygen and blood flow to the brain at or near the time of birth, remains a leading cause of neonatal mortality and long-term neurological impairments globally.

Research 52

Research Clinical Trials Clinical Trials Trials 52

Advertisement

Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.

Life Science